tru Independence’s DexCom DXCM Stock Holding History

tru Independence’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-400	Closed	-$41	–	469
2020 Q2	$41	Hold	400	–	–	0.01%	404
2020 Q1	$27	Hold	400	–	–	﹤0.01%	356
2019 Q4	$27K	Buy	+400	New	+$19K	﹤0.01%	445

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

tru Independence's DXCM Position: Q3 2020 in Review

tru Independence sold out of DexCom (DXCM) in Q3 2020, closing a stake of 400 shares — an estimated $41 sold.

tru Independence first reported a position in DXCM in Q4 2019 and held it in 3 quarters. The position peaked at $27K in Q4 2019. 727 funds tracked by Wall St. Rank hold DXCM as of Q3 2020.

tru Independence reported no remaining DexCom position as of Q3 2020 after selling out during the quarter.
tru Independence sold 400 DexCom shares in Q3 2020, an estimated $41.
tru Independence first reported a position in DexCom in Q4 2019 and held it in 3 quarters.
tru Independence's DexCom position peaked at $27K in Q4 2019.
727 funds tracked by Wall St. Rank held DexCom as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.